Recent reports have provided evidence that the extracellular domain of CA IX can be released into body fluids and serve as a prognostic biomarker in patients with renal cell carcinoma [17], breast cancer [18], non-small cell lung cancer [19], or rectal cancer [20]. Here, CA9 is linked to rectal cancer.